Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

Recruiting

Phase 2

ABX-002Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

Sponsor:

Autobahn Therapeutics, Inc.

Code:

NCT06633016

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

ABX-002

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Autobahn Therapeutics, Inc. on 2025-02-14.